What is it about?
Giant cell arteritis and its treatment can have a negative impact on quality of life. This research developed an new disease-related patient-reported outcome measure - the GCA-PRO. This can be used in clinical trials and clinical practice.
Featured Image
Photo by Tolga Ulkan on Unsplash
Why is it important?
The GCA PRO has excellent measurement validity and reliability and can be used with confidence in clinical and research contexts alongside other measures for people with different types of giant cell arteritis.
Read the Original
This page is a summary of: Validation of a patient-reported outcome measure for giant cell arteritis, Rheumatology, May 2023, Oxford University Press (OUP),
DOI: 10.1093/rheumatology/kead201.
You can read the full text:
Contributors
The following have contributed to this page
